PE20171327A1 - Formas cristalinas de un compuesto de pirrolopiridina - Google Patents

Formas cristalinas de un compuesto de pirrolopiridina

Info

Publication number
PE20171327A1
PE20171327A1 PE2017001459A PE2017001459A PE20171327A1 PE 20171327 A1 PE20171327 A1 PE 20171327A1 PE 2017001459 A PE2017001459 A PE 2017001459A PE 2017001459 A PE2017001459 A PE 2017001459A PE 20171327 A1 PE20171327 A1 PE 20171327A1
Authority
PE
Peru
Prior art keywords
crystalline forms
pyrrolopyridine compound
pyrrolopyridine
compound
aminopiperidin
Prior art date
Application number
PE2017001459A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey Stults
Christopher M Lindemann
Keith L Spencer
Weidong Liu
Joseph Lubach
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of PE20171327A1 publication Critical patent/PE20171327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2017001459A 2015-02-26 2016-02-26 Formas cristalinas de un compuesto de pirrolopiridina PE20171327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26

Publications (1)

Publication Number Publication Date
PE20171327A1 true PE20171327A1 (es) 2017-09-12

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001459A PE20171327A1 (es) 2015-02-26 2016-02-26 Formas cristalinas de un compuesto de pirrolopiridina

Country Status (21)

Country Link
US (2) US20160251350A1 (cg-RX-API-DMAC7.html)
EP (1) EP3262042A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018506562A (cg-RX-API-DMAC7.html)
KR (1) KR20170118762A (cg-RX-API-DMAC7.html)
CN (1) CN107406447A (cg-RX-API-DMAC7.html)
AR (1) AR103801A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016225070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017018230A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976665A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017009662A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170439A (cg-RX-API-DMAC7.html)
HK (1) HK1246786A1 (cg-RX-API-DMAC7.html)
IL (1) IL254115A0 (cg-RX-API-DMAC7.html)
MA (1) MA41599A (cg-RX-API-DMAC7.html)
MX (1) MX2017010888A (cg-RX-API-DMAC7.html)
PE (1) PE20171327A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501532A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017133093A (cg-RX-API-DMAC7.html)
SG (1) SG11201706824TA (cg-RX-API-DMAC7.html)
WO (1) WO2016138458A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
HK1246786A1 (zh) 2018-09-14
CN107406447A (zh) 2017-11-28
BR112017018230A2 (pt) 2018-04-17
CL2017002180A1 (es) 2018-03-16
IL254115A0 (en) 2017-10-31
KR20170118762A (ko) 2017-10-25
CR20170439A (es) 2018-01-08
RU2017133093A (ru) 2019-03-26
EP3262042A1 (en) 2018-01-03
WO2016138458A1 (en) 2016-09-01
AU2016225070A1 (en) 2017-09-07
US20180282324A1 (en) 2018-10-04
US20160251350A1 (en) 2016-09-01
RU2017133093A3 (cg-RX-API-DMAC7.html) 2019-08-23
PH12017501532A1 (en) 2018-02-05
CA2976665A1 (en) 2016-09-01
AR103801A1 (es) 2017-06-07
MA41599A (fr) 2018-01-02
JP2018506562A (ja) 2018-03-08
CO2017009662A2 (es) 2018-02-28
MX2017010888A (es) 2017-12-15
SG11201706824TA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
IL275639A (en) Formulation for RNA administration
GEP20207074B (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
AR096758A1 (es) Inhibidores cristalinos de bromodominios
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
DK3529241T3 (da) Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
GEP20207076B (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
DK3412672T3 (da) Krystalform A af 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D]pyrimidin-4-amin som TLR7-agonist, fremstillingsfremgangsmåde og anvendelse deraf
MX2017000134A (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3 ,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carb oxamida.
MX384201B (es) Proceso para la preparacion de treprostinil.
MX2019015744A (es) Composiciones farmaceuticas.
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
HUE051693T2 (hu) 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái
UY35535A (es) ?Derivados de fenil sulfonamidas?.
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
CR20190344A (es) Activador de nrf2
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
UY35536A (es) ?derivados de sulfonamida?.
CO2017009662A2 (es) Formas cristalinas de un compuesto de pirrolopiridina
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX381590B (es) Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.
IL290625A (en) Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use
IL283656A (en) New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
MX2020009412A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
DK3935047T3 (da) Fremgangsmåde til fremstilling af et substitueret imidazoquinolin